Identifying and assessing benefit-risk in primary care--a family physician's perspective
- PMID: 20407137
- PMCID: PMC2857793
- DOI: 10.1093/rheumatology/keq059
Identifying and assessing benefit-risk in primary care--a family physician's perspective
Abstract
For the family physician, NSAIDs, both traditional and cyclo-oxygenase-2 inhibitors, are a valuable contribution to managing arthritis and other rheumatological conditions in primary care. Yet, many of the patients seen by the family doctor have complex comorbidities and polypharmacy issues. This review looks at the main considerations for primary-care physicians while choosing an anti-inflammatory treatment for a hypothetical patient case study. In addition to looking at the evidence for gastrointestinal and cardiovascular risk, the concomitant use of aspirin with an NSAID is also examined. New evidence for interaction between selective serotonin re-uptake inhibitors is reviewed and the interaction between angiotensin-converting enzyme inhibitors and NSAIDs is considered. Making careful judgements based on individual needs, medical history and comorbidities is recommended based on the evidence reviewed.
Figures

Similar articles
-
Patient benefit-risk in arthritis--a rheumatologist's perspective.Rheumatology (Oxford). 2010 May;49 Suppl 2(Suppl 2):ii11-17. doi: 10.1093/rheumatology/keq057. Rheumatology (Oxford). 2010. PMID: 20407136 Free PMC article. Review.
-
Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.Aliment Pharmacol Ther. 2004 Jan 15;19(2):197-208. doi: 10.1111/j.0269-2813.2004.01834.x. Aliment Pharmacol Ther. 2004. PMID: 14723611 Review.
-
Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey.Aliment Pharmacol Ther. 2006 Mar 1;23(5):655-68. doi: 10.1111/j.1365-2036.2006.02810.x. Aliment Pharmacol Ther. 2006. PMID: 16480405
-
Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.Arthritis Res Ther. 2005;7 Suppl 4(Suppl 4):S14-22. doi: 10.1186/ar1794. Epub 2005 Sep 15. Arthritis Res Ther. 2005. PMID: 16168077 Free PMC article. Review.
-
Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.Nat Clin Pract Gastroenterol Hepatol. 2006 Oct;3(10):563-73. doi: 10.1038/ncpgasthep0610. Nat Clin Pract Gastroenterol Hepatol. 2006. PMID: 17008926 Review.
Cited by
-
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.Rheumatol Int. 2012 Jun;32(6):1491-502. doi: 10.1007/s00296-011-2263-6. Epub 2011 Dec 23. Rheumatol Int. 2012. PMID: 22193214 Free PMC article. Review.
References
-
- Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a Safer Health System. Washington, DC: National Academy Press; 1999. - PubMed
-
- Todd PA, Clissold SP. Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs. 1990;40:91–137. - PubMed
-
- American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis Rheum. 2000;43:1905–15. - PubMed
-
- Maurer PM, Bartkowski RR. Drug interactions of clinical significance with opioid analgesics. Drug Saf. 1993;8:30–48. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical